Shiraishi M, Hiroyasu S, Oshiro T, Nagahama M, Tomori H, Mamadi T, Muto Y
School of Medicine, University of the Ryukyus, Uehara 207, Nishihara-cho, Okinawa, 903-0215, Japan.
J Surg Res. 1999 Sep;86(1):136-44. doi: 10.1006/jsre.1999.5706.
The liver is one of the primary targets of acute graft-versus-host disease (GVHD), which is the principal complication that occurs after allogeneic intestinal transplantation. The purpose of this study is to investigate the involvement of the Fas/Fas ligand system in hepatic GVHD after rat semiallogeneic intestinal transplantation.
Liver samples were serially harvested from LEW x BN F(1) (LBNF(1)) recipients of either LEW heterotopic intestinal allografts (group 1) or LBNF(1) isografts (group 2), on Days 1, 3, 5, 9, and 13 posttransplant.
In group 1, hepatic injuries as assessed by either serum aspartate aminotransferase (AST) level, alanine aminotransferase (ALT) level, or cellular infiltration on HE staining became apparent after Day 13. The incidence of apoptosis, examined by terminal deoxynucleotidyl transferase-mediated dUTP biotin nick end-labeling (TUNEL), was observed to steadily increase in the liver from Day 5 accompanied by a progression of GVHD: 17.5 +/- 3.1 and 3.1 +/- 0.4 cells/field (200x) in groups 1 and 2, respectively. In an immunohistochemical study, Fas was constitutively expressed in the liver in both groups, while Fas ligand was expressed most extensively on Day 13 in group 1. Immunoreactivity of both Fas and Fas ligand was observed in hepatocytes, in addition to leukocytes. Analysis by reverse transcription polymerase chain reaction also revealed the expression of Fas mRNA to be constitutive in both groups, while that of Fas ligand mRNA increased significantly from Day 5 and peaked on Day 13 in group 1, and the expression was 10 times stronger than that for isogeneic combination (group 2).
Early detection of upregulated Fas ligand and increased apoptosis is thus considered to be potentially a useful tool for the diagnosis of hepatic GVHD.
肝脏是急性移植物抗宿主病(GVHD)的主要靶器官之一,急性GVHD是同种异体小肠移植后发生的主要并发症。本研究旨在探讨Fas/Fas配体系统在大鼠半同种异体小肠移植后肝GVHD中的作用。
在移植后第1、3、5、9和13天,从接受LEW异位小肠同种异体移植的LEW×BN F(1)(LBNF(1))受体(第1组)或LBNF(1)同基因移植受体(第2组)中连续采集肝脏样本。
在第1组中,通过血清天冬氨酸转氨酶(AST)水平、丙氨酸转氨酶(ALT)水平或HE染色的细胞浸润评估的肝损伤在第13天后变得明显。通过末端脱氧核苷酸转移酶介导的dUTP生物素缺口末端标记(TUNEL)检测的凋亡发生率,从第5天起在肝脏中稳步增加,同时伴有GVHD的进展:第1组和第2组分别为17.5±3.1和3.1±0.4个细胞/视野(200倍)。在免疫组织化学研究中,两组肝脏中Fas均组成性表达,而Fas配体在第1组中第13天表达最为广泛。除白细胞外,在肝细胞中也观察到Fas和Fas配体的免疫反应性。逆转录聚合酶链反应分析还显示,两组中Fas mRNA的表达均为组成性,而Fas配体mRNA的表达从第5天起显著增加,并在第1组中第13天达到峰值,其表达比同基因组合(第2组)强10倍。
因此,早期检测到Fas配体上调和凋亡增加可能是诊断肝GVHD的有用工具。